Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Acquisitions & Divestments (2023)

OptimizeRx's Change in Acquisitions & Divestments history spans 1 years, with the latest figure at $53.6 million for Q4 2023.

  • For Q4 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $53.6 million; the TTM value through Dec 2023 reached $218.7 million, changed N/A, while the annual FY2023 figure was $218.7 million, N/A changed from the prior year.
  • Change in Acquisitions & Divestments for Q4 2023 was $53.6 million at OptimizeRx, up from $52.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $56.9 million in Q2 2023 and bottomed at $52.6 million in Q3 2023.